Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO) filed a Current Report on Form 8-K on August 12, 2019. The filing announces the release of results of operations for the quarter ended June 30, 2019. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) containing the actual financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in this specific filing text, as the quantitative results are contained in the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release will not be treated as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2019) for specific Q2 2019 financial figures.
- Verify the company's cash position and runway given the lack of revenue data in the summary text.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's emerging growth company election and any related accounting transitions.